Select Page

MYELOMA360 is a novel insight-led community for biopharmaceutical companies and healthcare professionals centralizing information, ideas and education to address these issues. It brings independent, unbiased expertise and opinion to the community, to help improve the lives of patients living with multiple myeloma.

The treatment of multiple myeloma has never been so opportunistic, yet so complicated. With 30+ approved drugs, treatments and advanced diagnostic and prognostic testing, community clinicians are unsure about best treatment / management decisions.

Myeloma is a complicated disease to accurately diagnose and treat. Drug development in myeloma is increasingly challenging and requires expert insights to best navigate a successful development plan.

Myeloma News

LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway

Source: Myeloma : nature.com subject feeds Post Content Read More

Evolving Frontline Treatments for Patients With Newly Diagnosed Multiple Myeloma: Quadruplet Regimens Show Promise

Source: Pharmacy Times articles IMROZ study data show Isa-VRd may be a new standard of care. Read More

Pembrolizumab and Radiotherapy Treatment Demonstrates Efficacy in Patients With Relapsed, Refractory Multiple Myeloma

Source: Pharmacy Times articles Radiotherapy may have applications beyond symptomatic relief when used in combination with immunotherapy. Read More

Recent Myeloma Publications

Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma

J Palliat Med. 2024 Jul 11. doi: 10.1089/jpm.2023.0530. Online ahead of print. ABSTRACT...

Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma

Clin Cancer Res. 2024 Jul 11. doi: 10.1158/1078-0432.CCR-24-0117. Online ahead of print. ABSTRACT...

RASping myeloma genomics

Blood. 2024 Jul 11;144(2):129-131. doi: 10.1182/blood.2024024869. NO ABSTRACT PMID:38990540 |...

Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma

Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.285470. Online ahead of print. ABSTRACT...